Lysine

Lysine

SCHEMBL456381

NCCCCC(N)C(=O)O.NCCCC[C@H](N)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 1.00
ARG2 P78540 4/20 0.59
ARG1 P05089 3/20 0.59
RNPEP Q9H4A4 1/20 0.58
CYP1A2 P05177 3/20 0.52
GRM8 O00222 1/20 0.52
GRM6 O15303 1/20 0.52
GRIN2D O15399 1/20 0.52
GRIN3B O60391 1/20 0.52
GRIK1 P39086 1/20 0.52
GRM5 P41594 1/20 0.52
GRIA1 P42261 1/20 0.52
GRIA2 P42262 1/20 0.52
GRIA3 P42263 1/20 0.52
SLC1A3 P43003 1/20 0.52
SLC1A2 P43004 1/20 0.52
SLC1A1 P43005 1/20 0.52
GRIA4 P48058 1/20 0.52
GRIN1 Q05586 1/20 0.52
GRIN2A Q12879 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lysine SCHEMBL2802757 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL8613373 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL3359527 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL1645 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL12867528 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL1000151 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL9439278 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL20362357 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL7343 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2
Lysine SCHEMBL15303774 1.00 GSR (1.00) GSRARG2ARG1RNPEPCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1520073-B1 TRIAZINNYLAMINOSTILBENE DISULPHONIC ACID MIXTURES BASF SE (DE) 2012-01-18 EP claimed
US-20110286915-A1 Nanocarriers for Drug Delivery THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-11-24 US claimed
EP-2344134-A2 NANOCARRIERS FOR DRUG DELIVERY The Regents of the University of California (US) 2011-07-20 EP claimed
EP-2292837-A1 Triazinylaminostilbene disulphonic acid mixtures BASF SE (DE) 2011-03-09 EP claimed
WO-2012052096-A1 METHOD TO CONTROL AND VALIDATE THE QUALITY OF QUANTITATIVE ANALYSIS OF BIOLOGICAL SAMPLES METABOLOMIC DISCOVERIES GMBH (DE) 2012-04-26 WO disclosed
EP-1520073-B1 TRIAZINNYLAMINOSTILBENE DISULPHONIC ACID MIXTURES BASF SE (DE) 2012-01-18 EP disclosed
US-20110286915-A1 Nanocarriers for Drug Delivery THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-11-24 US disclosed
US-8044166-B2 Process for preparing pentamethylene 1,5-diisocyanate BASF AKTIENGESELLSCHAFT (DE) 2011-10-25 US disclosed
EP-2344134-A2 NANOCARRIERS FOR DRUG DELIVERY The Regents of the University of California (US) 2011-07-20 EP disclosed
US-7914979-B2 Preparing preservative mixture for storage of newcastle disease virus WELLSTAT BIOLOGICS CORPORATION (US) 2011-03-29 US disclosed
US-7911035-B2 Directionally controlled growth of nanowhiskers QUNANO AB (SE) 2011-03-22 US disclosed
EP-2292837-A1 Triazinylaminostilbene disulphonic acid mixtures BASF SE (DE) 2011-03-09 EP disclosed
US-20110033517-A1 COATINGS FOR IMPLANTABLE MEDICAL DEVICES COMPRISING HYDROPHILIC SUBSTANCES AND METHODS FOR FABRICATING THE SAME ADVANCED CARDIOVASCULAR SYSTEMS, INC. 2011-02-10 US disclosed
EP-0487632-A1 STABILIZED VACCINE COMPOSITIONS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1992-06-03 EP disclosed
WO-1991002543-A1 STABILIZED VACCINE COMPOSITIONS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1991-03-07 WO disclosed
US-3994688-A REACTING L-LYSINE WITH A G-FORMYL-PYRIDINE DERIVATIVE A/S N. FOSS ELECTRIC (DK) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033517-A1 COATINGS FOR IMPLANTABLE MEDICAL DEVICES COMPRISING HYDROPHILIC SUBSTANCES AND METHODS FOR FABRICATING THE SAME CD99, CD44, PUF60 GSR 4336/4885ARG2 3137/4885ARG1 617/4885
US-20110286915-A1 Nanocarriers for Drug Delivery CLTA, EPCAM, EGFR GSR 1966/4885ARG2 2821/4885ARG1 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.